Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.90 |
| ▸ | MAPT | P10636 | 2/20 | 0.90 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.90 |
| ▸ | HPGD | P15428 | 2/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8554591 | 0.98 | RAB9A (0.87) | RAB9AMAPTSMN1; SMN2HPGDNPSR1 | |
| SCHEMBL11996369 | 0.98 | RAB9A (0.87) | RAB9AMAPTSMN1; SMN2HPGDNPSR1 | |
| SCHEMBL7299163 | 0.95 | RAB9A (1.00) | RAB9AMAPTSMN1; SMN2HPGDNPSR1 | |
| SCHEMBL8483472 | 0.91 | RAB9A (0.74) | RAB9AMAPTSMN1; SMN2HPGDNPSR1 | |
| SCHEMBL1578469 | 0.89 | RAB9A (0.83) | RAB9AMAPTSMN1; SMN2HPGDNPSR1 | |
| SCHEMBL10682756 | 0.89 | RAB9A (0.72) | RAB9AMAPTSMN1; SMN2HPGDNPSR1 | |
| SCHEMBL10683303 | 0.89 | RAB9A (0.72) | RAB9AMAPTSMN1; SMN2HPGDNPSR1 | |
| SCHEMBL10680795 | 0.89 | RAB9A (0.72) | RAB9AMAPTSMN1; SMN2HPGDNPSR1 | |
| SCHEMBL10675006 | 0.89 | RAB9A (0.72) | RAB9AMAPTSMN1; SMN2HPGDNPSR1 | |
| SCHEMBL10683824 | 0.89 | RAB9A (0.72) | RAB9AMAPTSMN1; SMN2HPGDNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3268435-B1 | POLYMERIC BODIPY DYES AND METHODS FOR USING THE SAME | BECTON DICKINSON CO (US) | 2022-07-13 | — | — | EP | disclosed |
| US-10240004-B2 | Polymeric BODIPY dyes and methods for using the same | BECTON, DICKINSON AND COMPANY (US) | 2019-03-26 | — | — | US | disclosed |
| US-20170335067-A1 | POLYMERIC BODIPY DYES AND METHODS FOR USING THE SAME | BECTON, DICKINSON AND COMPANY | 2017-11-23 | — | — | US | disclosed |
| US-9719998-B2 | Ultraviolet absorbing polymeric dyes and methods for using the same | BECTON DICKINSON AND COMPANY (US) | 2017-08-01 | — | — | US | disclosed |
| US-7960380-B2 | Non-anilinic derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators | ASTRAZENECA AB (SE) | 2011-06-14 | — | — | US | disclosed |
| US-20100227847-A1 | Non-Anilinic Derivatives Of Isothiazol-3(2H)-one 1,1-Dioxides As Liver X Receptor Modulators | ASTRAZENECA AB (SE) | 2010-09-09 | — | — | US | disclosed |
| US-7723333-B2 | Non-anilinic derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators | ASTRAZENECA AB (SE) | 2010-05-25 | — | — | US | disclosed |
| US-20090005353-A1 | Non-Anilinic Derivatives of Isothiazol-3(2H)-one 1,1-Dioxides as Liver X Receptor Modulators | ASTRAZENECA AB (SE) | 2009-01-01 | — | — | US | disclosed |
| EP-1838687-A1 | NON-ANILINIC DERIVATIVES OF ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2007-10-03 | — | — | EP | disclosed |
| WO-2006073366-A1 | NON-ANILINIC DERIVATIVES OF ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2006-07-13 | — | — | WO | disclosed |
| EP-0491374-B1 | Bisphosphonic acid derivatives, their production and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1996-01-31 | — | — | EP | disclosed |
| US-5280022-A | Containing an amine group | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-01-18 | — | — | US | disclosed |
| EP-0491374-A1 | Bisphosphonic acid derivatives, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1992-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005353-A1 | Non-Anilinic Derivatives of Isothiazol-3(2H)-one 1,1-Dioxides as Liver X Receptor Modulators | NR1H2, NR1H3, NR1I2 | RAB9A 3641/4885MAPT 2119/4885SMN1; SMN2 4033/4885 |
| US-20100227847-A1 | Non-Anilinic Derivatives Of Isothiazol-3(2H)-one 1,1-Dioxides As Liver X Receptor Modulators | NR1H2, NR1H3, NR1I2 | RAB9A 3641/4885MAPT 2119/4885SMN1; SMN2 4033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.